The NICE has issued final draft guidance endorsing the use of CSL Vifor's Filspari (sparsentan) for primary IgA nephropathy.

Aptar Digital Health has signed a licensing agreement with AstraZeneca for detecting CKD using the latter’s AI-driven ...

In combination with Pfizer’s CDK4/6 inhibitor Ibrance (palbociclib) and anti-oestrogen drug Faslodex (fulvestrant), Itovebi ...

Evernorth said that through direct negotiations with Novo Nordisk and Eli Lilly, patients’ monthly copay costs for Wegovy ...

Eli Lilly and Company has received marketing authorisation from the Australian Therapeutic Goods Administration (TGA) for ...

The rise of GLP-1 agonist therapies has transformed obesity treatment, delivering unprecedented results and revealing their ...

Orionis Biosciences has announced a multi-year partnership with Roche’s Genentech for small-molecule monovalent glue medicine ...

The Trump administration’s budget reconciliation bill has passed the US House of Representatives by a wafer-thin single-vote ...

UK biopharmaceutical companies saw a surge in venture financing for innovator drugs in 2024, with double the total deal value ...

Paratek Pharmaceuticals has completed the acquisition of Optinose, valued at almost $330m, broadening its commercial product ...

Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act. The EU Artificial Intelligence (AI ...